What is the best time of day to inject Magnus Nandro D 250mg/ml?

Morning injections — typically within the first two hours after waking — are preferred by most structured users because cortisol is naturally elevated at that time, and a fresh Nandrolone Decanoate depot counteracts its catabolic signalling during the day's most demanding training window. If training occurs in the late afternoon, shifting the injection to two to three hours pre-session can better align drug absorption onset with peak anabolic demand.

Does it matter which specific days of the week I inject Nandrolone Decanoate when using a 10ml vial?

Yes — day selection directly affects plasma trough depth. For a twice-weekly protocol, spacing injections approximately 84 hours apart (e.g. Monday and Thursday) minimises the drop below anabolic threshold before the next dose. Consistent fixed days matter more than the specific days chosen; irregular spacing introduces unnecessary plasma variability that undermines steady anabolic output across the week.

Should I inject Nandro D before or after my weight-training session?

Pre-training injection — ideally two to four hours before lifting — is the preferred approach, as it aligns the early absorption phase of the decanoate depot with the exercise-induced hormonal environment. Post-training injection is an acceptable alternative but misses the potential overlap between training-stimulated nutrient uptake and incoming drug substrate. Either timing is valid; consistency with your chosen window is the deciding factor.

How should a 10ml vial of Nandro D 250mg/ml be stored after the first draw?

Store the opened vial at room temperature (15–25 °C), away from direct light, and avoid refrigeration — chilling oil-based injectables can cause the carrier oil to thicken, making accurate drawing into a syringe more difficult. Handle the rubber septum under strict aseptic technique at each draw. Discard any remaining product if the solution becomes cloudy, discoloured, or shows visible particulate matter.

Can I draw Magnus Nandro D into an insulin syringe, and does concentration affect measurement accuracy?

Standard 1 ml insulin syringes (29–31 gauge, 0.5 inch needle) are generally not recommended for oil-based injectables at 250 mg/ml because the viscosity of the carrier oil makes drawing slow and the short needle is unsuitable for deep intramuscular delivery. A 23–25 gauge, 1–1.5 inch syringe provides accurate measurement and sufficient depth. Draw volumes are clean at this concentration: 1.0 ml = 250 mg, simplifying dose calculation without conversion. (2) angle_used

Athletes' Choice

Magnus Pharmaceuticals

Nandro D 250mg/ml 10ml Vial by Magnus Pharmaceuticals

Name: Nandro D 250mg/ml 10ml Vial by Magnus Pharmaceuticals
Brand: Magnus Pharmaceuticals
SKU: INJ-NAND-MAG-250-013
Price: 48.00 EUR
Availability: InStock

Magnus Pharmaceuticals Nandro D delivers Nandrolone Decanoate at a precisely filled 250 mg/ml concentration in a 10 ml multi-dose vial, purpose-engineered for structured weekly injection scheduling that keeps plasma levels stable across a full training week. Strategic timing of each dose — anchored to consistent days and training session proximity — determines how smoothly anabolic output tracks with workout demand. Quality is enforced at every production stage: HPLC potency verification, LAL endotoxin testing, and GMP-certified filling are standard for every batch leaving the Magnus facility.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Precisely filled 250 mg/ml concentration supports clean twice-weekly dose arithmetic (1.0 ml = 250 mg per injection).
Extended active window enables structured Monday/Thursday scheduling without daily administration burden.
HPLC-verified potency ensures the labelled dose matches what reaches systemic circulation at each timed injection.
10 ml vial volume sustains a full ten-week twice-weekly protocol from a single unit without mid-cycle reordering.
LAL endotoxin-cleared oil base reduces injection-site inflammatory response, supporting consistent training attendance around injection days.
GMP-manufactured under controlled filling conditions, minimising particulate risk that could otherwise disrupt a scheduled administration routine.
Magnus Pharmaceuticals' documented batch consistency allows users to standardise timing protocols across consecutive cycles without recalibrating for potency drift.

Phase	Dosage	Timing Note
Introductory (Weeks 1–2)	250 mg/week (1.0 ml × 1 injection)	Single injection on a fixed morning; establishes depot and calibrates individual response before adding a second weekly shot
Standard Build (Weeks 3–10)	500 mg/week (1.0 ml × 2 injections)	Monday morning + Thursday evening (~84 hours apart); pre-training placement preferred for each injection day
Moderate / Sensitivity-Conscious (Weeks 3–16)	250–350 mg/week (1.0–1.4 ml split across 2 injections)	Lower-frequency users who prefer a single weekly shot should choose a consistent morning slot linked to their heaviest training session
Taper / Wind-Down (Final 2 Weeks)	125–250 mg/week (0.5–1.0 ml)	Reduce to single weekly injection; maintain fixed day to allow orderly plasma decline before PCT initiation

Key takeaways

Schedule injections on fixed calendar days to prevent plasma trough variability.
Split weekly doses 84 hours apart for tighter Nandrolone plasma stability.
Administer two to four hours pre-training to align depot onset with workout demand.
Store the opened vial at room temperature; avoid refrigeration of oil-based injectables.
Verify each batch's HPLC certificate before committing to a timing protocol.

What Optimal Injection Timing Means for Nandrolone Decanoate Users

Magnus Pharmaceuticals Nandro D is a 250 mg/ml Nandrolone Decanoate injectable whose clinical value depends not only on dose magnitude but on the day-of-week and time-of-day framework within which each injection is placed. Unlike short-ester compounds that demand near-daily administration, Nandrolone Decanoate's extended active window — approximately six to seven days per conventional pharmacokinetic modelling — allows a once- or twice-weekly schedule; however, the precise positioning of those injections within the week governs how close plasma troughs come to falling below the anabolic threshold before the next dose arrives.

Day-of-Week Scheduling and Plasma Trough Management

Twice-weekly dosing consistently outperforms single weekly injection for trough stability according to plasma-concentration modelling published in endocrinological pharmacokinetics literature. Splitting a 500 mg weekly dose into two 250 mg administrations placed roughly 84 hours apart — for example Monday morning and Thursday evening — compresses the peak-to-trough swing compared to a single Sunday injection. Magnus Nandro D at 250 mg/ml makes this protocol arithmetically clean: each injection draws exactly 1.0 ml, removing measurement ambiguity during the administration window. The 10 ml vial therefore covers a full ten-week cycle at this frequency without requiring additional unit purchases mid-protocol.

Timing Relative to Training Sessions

Injection timing relative to resistance training carries a distinct rationale separate from day scheduling. Administering Nandro D within two to four hours before a heavy compound session allows the acute hormonal environment — already primed by training-induced testosterone release measured via salivary assay in exercise physiology studies — to overlap with freshly deposited depot drug. Compared to injecting on complete rest days, this pre-training placement aligns substrate availability with the window of maximal skeletal-muscle nutrient uptake documented in post-exercise isotope-tracing studies. Magnus Pharmaceuticals manufactures Nandro D under GMP conditions; each vial undergoes HPLC-confirmed concentration verification and LAL endotoxin screening before release, ensuring that the 250 mg/ml label claim is reliably met at the point of injection regardless of timing strategy chosen.

Sustaining Schedule Consistency Through a Full Cycle

Schedule adherence matters as much as initial placement. Drifting injection days by more than 24 hours introduces unnecessary variability into trough plasma levels; Magnus Nandro D users should designate fixed calendar slots and treat them with the same consistency applied to structured training sessions. A practical approach: link each injection day to a recurring training event so that the habit is reinforced by existing behaviour architecture rather than relying solely on manual reminders.

Usage

Select your two fixed injection days for the week — Monday and Thursday work well — and link each to a recurring training event so the schedule becomes automatic rather than dependent on manual reminders.
Remove the Nandro D vial from storage at least 30 minutes before drawing; allowing the oil to reach room temperature reduces viscosity and makes accurate measurement easier.
Wipe the rubber septum with a fresh alcohol swab and draw the required volume using a 21-gauge needle to fill the syringe; switch to a 23–25 gauge, 1–1.5 inch needle for the actual injection.
Administer intramuscularly into the glute, vastus lateralis, or deltoid; aspirate briefly to confirm no intravascular placement, then inject slowly over 20–30 seconds.
Inject two to four hours before your training session on scheduled workout days to align the early absorption phase with peak anabolic demand during the lift.
Log each injection — date, time, volume drawn, and injection site — in a training journal or app; consistent record-keeping allows you to identify any schedule drift exceeding 24 hours and correct it before plasma variability compounds over successive weeks.

Warnings

Contraindications: Nandro D is contraindicated in individuals with known hypersensitivity to Nandrolone Decanoate or any carrier-oil excipient. It must not be used by individuals with active or suspected androgen-sensitive carcinoma, severe hepatic impairment, untreated polycythaemia, or during pregnancy and lactation. Female athletes should assess virilisation risk individually before commencing any Nandrolone Decanoate protocol.

Side Effects: Reported adverse effects include dose-dependent suppression of endogenous testosterone production, elevation of serum prolactin (characteristic of 19-nor compounds), fluid retention particularly around joints, and androgenic effects such as acne or accelerated scalp hair thinning in genetically predisposed individuals. Cardiovascular risk markers — including haematocrit, LDL, and HDL — should be monitored throughout the cycle.

Monitoring: Pre-cycle baseline bloodwork should include full hormonal panel (LH, FSH, total testosterone, prolactin, estradiol), lipid profile, haematocrit, liver enzymes, and blood pressure. Repeat panels at the cycle midpoint and at four weeks post-final injection. Cabergoline or bromocriptine should be on hand to manage prolactin elevation if serum values trend above the laboratory reference range during monitoring.

PCT: Begin post-cycle therapy no sooner than three weeks after the last Nandro D injection to allow sufficient plasma clearance of the decanoate ester. A standard SERM-based PCT (Nolvadex or Clomid) lasting four to six weeks supports HPTA recovery. Bloodwork at eight weeks post-PCT confirms whether endogenous testosterone and gonadotropin levels have returned to pre-cycle baseline before any subsequent protocol is considered.

Frequently asked questions

What is the best time of day to inject Magnus Nandro D 250mg/ml?: Morning injections — typically within the first two hours after waking — are preferred by most structured users because cortisol is naturally elevated at that time, and a fresh Nandrolone Decanoate depot counteracts its catabolic signalling during the day's most demanding training window. If training occurs in the late afternoon, shifting the injection to two to three hours pre-session can better align drug absorption onset with peak anabolic demand.
Does it matter which specific days of the week I inject Nandrolone Decanoate when using a 10ml vial?: Yes — day selection directly affects plasma trough depth. For a twice-weekly protocol, spacing injections approximately 84 hours apart (e.g. Monday and Thursday) minimises the drop below anabolic threshold before the next dose. Consistent fixed days matter more than the specific days chosen; irregular spacing introduces unnecessary plasma variability that undermines steady anabolic output across the week.
Should I inject Nandro D before or after my weight-training session?: Pre-training injection — ideally two to four hours before lifting — is the preferred approach, as it aligns the early absorption phase of the decanoate depot with the exercise-induced hormonal environment. Post-training injection is an acceptable alternative but misses the potential overlap between training-stimulated nutrient uptake and incoming drug substrate. Either timing is valid; consistency with your chosen window is the deciding factor.
How should a 10ml vial of Nandro D 250mg/ml be stored after the first draw?: Store the opened vial at room temperature (15–25 °C), away from direct light, and avoid refrigeration — chilling oil-based injectables can cause the carrier oil to thicken, making accurate drawing into a syringe more difficult. Handle the rubber septum under strict aseptic technique at each draw. Discard any remaining product if the solution becomes cloudy, discoloured, or shows visible particulate matter.
Can I draw Magnus Nandro D into an insulin syringe, and does concentration affect measurement accuracy?: Standard 1 ml insulin syringes (29–31 gauge, 0.5 inch needle) are generally not recommended for oil-based injectables at 250 mg/ml because the viscosity of the carrier oil makes drawing slow and the short needle is unsuitable for deep intramuscular delivery. A 23–25 gauge, 1–1.5 inch syringe provides accurate measurement and sufficient depth. Draw volumes are clean at this concentration: 1.0 ml = 250 mg, simplifying dose calculation without conversion. (2) angle_used

Manufacturer

Magnus Pharmaceuticals operates a distribution and logistics network structured to maintain cold-chain integrity and documentation continuity from production site to end-point delivery. Each Nandro D batch is assigned a unique lot code that travels with the shipment through every logistics node — distributor, regional hub, and final-mile carrier — allowing traceability to be confirmed at any stage rather than only at the point of manufacture. The company's regional distribution agreements require authorised partners to retain batch certificates of analysis on file, meaning that product authenticity can be verified independently of the central Magnus records system. Shipment packaging for oil-based injectables is designed to prevent temperature excursions during transit, with insulated secondary packaging specified for routes passing through climate-variable regions. This logistics architecture reflects Magnus Pharmaceuticals' positioning as a supplier accountable for product integrity not just at the factory gate but at the moment the vial is received by the end user.

Product details

Brand	Magnus Pharmaceuticals
Active ingredient	nandrolone decanoate
Also known as	Deca Durabolin, Deca, Nandrolone Decanoate, Nandro D, Magnus Pharmaceuticals Deca Durabolin
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-NAND-MAG-250-013

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Decandrol 200mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Decandrol 200mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Decandrol is an injectable anabolic steroid produced by Balkan Pharmaceuticals, delivering Nandrolone Decanoate at 200 mg per millilitre across a ten-ampoule pack — a formulation directly rooted in over six decades of pharmaceutical and clinical development of the nandrolone molecule. First synthesised in 1960, Nandrolone Decanoate evolved from early research compounds into one of the most studied anabolics in sports medicine and endocrinology literature. Quality assurance at the Chișinău facility is governed by GMP compliance, with each production batch subjected to HPLC potency verification and LAL endotoxin testing before release.

€44.00

High Concentration

Deca-Durabolin 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Beligas Pharmaceuticals Deca-Durabolin delivers 300 mg of Nandrolone Decanoate per millilitre in a 10 ml multi-dose vial, purpose-engineered for integration into structured, periodised cycle protocols where consistent anabolic stimulus and joint support are programmed across distinct training phases. At 300 mg/ml, each vial provides 3,000 mg of active compound — enough to sustain a full intermediate-length cycle from kickstart to planned taper without mid-cycle restocking. Quality assurance is baked into every stage of production: HPLC-verified potency, LAL endotoxin testing on each batch, and full-cycle GMP compliance underpin the consistency that modern cycle planners demand.

€52.00

Decadubol-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Decadubol-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Decadubol-250 is a long-chain esterified anabolic injectable in which Nandrolone Decanoate at 250 mg/ml is designed around an extended pharmacokinetic release profile, giving the compound one of the longest circulating half-lives among injectable androgens. The decanoate ester slows hydrolysis after intramuscular depot formation, sustaining active Nandrolone plasma concentrations across a 6–8-day elimination window. Quality assurance is embedded at every production step: HPLC-verified potency, LAL endotoxin screening, and GMP-compliant fill-finish — all carried out by BM Pharmaceuticals.

€45.00

Trusted Brand

DecaTrex 350mg/ml 10ml Vial by Concentrex Labs

DecaTrex by Concentrex Labs delivers Nandrolone Decanoate at 350 mg/ml in a 10 ml multi-dose vial, purpose-built for athletes who structure their year around defined cruise and blast phases rather than standalone cycles. Its elevated concentration minimises injection volume during high-dose blast windows while keeping weekly cruise doses manageable with a single, low-volume pull. Every production batch passes HPLC quantification for concentration accuracy and LAL endotoxin testing for sterility assurance; GMP-certified manufacturing protocols govern each step from API weighing through final vial sealing.

€52.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00